Naturhouse Health SA (NTH) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Naturhouse Health SA €2.17, price €2.43, upside -10.7%, quality 89 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Naturhouse Health SA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range €1.00 – €2.67 · fair‑value band €1.73 – €2.64 · the €2.43 price screens above the €2.17 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Naturhouse Health in your weekly email
Every Wednesday you see whether Naturhouse Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Naturhouse Health, S.A. operates in the nutrition and dietetics industry in Spain, Italy, France, Poland, and internationally. The company sells food supplements that are made from natural extracts to facilitate the consumption of various nutrients; and food and drinks, such as diet products for breakfast, snacks, and meal substitutes.
Show more
Naturhouse Health, S.A. operates in the nutrition and dietetics industry in Spain, Italy, France, Poland, and internationally. The company sells food supplements that are made from natural extracts to facilitate the consumption of various nutrients; and food and drinks, such as diet products for breakfast, snacks, and meal substitutes. It also offers cosmetics and body care products, including beauty products related to skincare during the slimming process comprising cellulite, firming products, etc.; and anti-ageing products. In addition, the company engages in the production, preparation, and marketing of dietary products; and marketing of medicinal herbs and natural cosmetics. It sells its products through directly operated stores and franchised Naturhouse centers. The company was formerly known as Housediet, S.L.U. and changed its name to Naturhouse Health, S.A. Naturhouse Health, S.A. was incorporated in 1991 and is based in Madrid, Spain. Naturhouse Health, S.A. is a subsidiary of Kiluva S.A.
Stock analysis
Naturhouse Health SA (NTH) currently trades at €2.43, while our model-based Fair Value estimate is €2.17, implying the stock looks roughly 12.0% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of €2.80 per share, and 6 of the 24 models we run sit above the €2.43 price.
Bear case: the Economic Profit group reads lowest at €0.9400, and 18 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: €1.73 (bear) to €2.64 (bull), the price of €2.43 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 89/100 (high quality), in the Consumer Defensive sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Naturhouse Health SA reported revenue of €47.6M in FY2025 versus €57.6M in FY2021, a compound −4.6%/yr. Reported net income was €10.1M in FY2025, compounding −6.8%/yr from FY2021.
Key figures
Market cap €144M · P/E ratio 14.3 · P/S ratio 3.03 · EPS (TTM) €0.1700 · Dividend yield 11.7% · Net margin 21.2% · Return on equity 40.8% · Return on assets (EBIT) 33.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 9% below its 52-week high and 33% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −2% fair-value upside, at −11%, NTH screens richer than that median.
Fair Value models
Bear €1.73Fair Value €2.17Bull €2.64
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€0.1248 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−3.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.9%
Start year 2020 (pandemic). Over 10 years: −6.7% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+6.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−5.1%
Dividend (yield on the price)11.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−5% vs −8%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.24% → 28%
Start year 2020 (pandemic)
⚠ Revenue per share shrinking 6.4%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+5.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +2.8% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 667 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score89 · Top 25%
Fair Value upside−11% · Below median
Profitability
Return on equity (TTM)41% · Top 25%
Return on assets22% · Top 25%
Net margin (TTM)21% · Top 25%
Operating margin (TTM)24% · Top 25%
Growth and dividend
Revenue growth−1% · Below median
Dividend yield (TTM)11.7% · Top 25%
Valuation Multiplesvs Packaged Foods median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Naturhouse Health SA Fair Value". https://www.fairvalue-calculator.com/stock/NTH
Frequently asked questions
Is Naturhouse Health SA (NTH) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €2.17 versus a price of €2.43, about −11% upside (overvalued).
What is the fair value of NTH?
Our model-based fair value for Naturhouse Health SA is €2.17 (as of Sep 23, 2026), built from audited fundamentals. The current price: €2.43.
What is the quality score of NTH?
Naturhouse Health SA has a Quality Score of 89/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Naturhouse Health SA (NTH)?
Our model-based price target is the fair value of €2.17 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario €1.73, optimistic scenario €2.64. It is a calculation from audited fundamentals, not an analyst target.
What is the Naturhouse Health SA stock forecast for 2026?
Our models put fair value at €2.17, about −11% upside versus a price of €2.43 (overvalued). Cautious scenario €1.73, optimistic scenario €2.64. The calculation is refreshed regularly with new filings.
What is the revenue of Naturhouse Health SA (NTH)?
Naturhouse Health SA reported trailing-twelve-month revenue of about €47.6M (latest available figure, as of Sep 23, 2026).
Does Naturhouse Health SA pay a dividend?
Naturhouse Health SA currently shows a dividend yield of about 11.73% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Naturhouse Health SA (NTH)?
For today's price to be fair in a discounted-cash-flow model, Naturhouse Health SA would have to grow free cash flow by +5.0 % per year for five years (discount rate 12.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -2.9 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of NTH use?
Our models discount Naturhouse Health SA at 12.6 %: a base by market capitalisation (micro), damped by beta 0.34, country premium for Spain. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Naturhouse Health SA that is +5.0 % per year a year over ten years, using the same discount rate (12.6 %) and the same formula as our fair value.
How much growth has Naturhouse Health SA (NTH) delivered so far?
Over the past 5 years revenue at Naturhouse Health SA grew -2.9 % a year. The price currently implies +5.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Naturhouse Health SA (NTH) growing?
The median revenue growth in the sector is +2.6 % a year. That is the yardstick for the growth priced into Naturhouse Health SA (+5.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Naturhouse Health SA (NTH)?
The free-cash-flow yield on the price is 7.96 %: that much free cash flow Naturhouse Health SA produces per unit of market value. When it exceeds the discount rate of our models (12.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Naturhouse Health SA (NTH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Naturhouse Health SA it is €2.17 per share (as of Sep 23, 2026), against a price of €2.43. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Naturhouse Health SA stock overvalued or undervalued in 2026?
As of Sep 23, 2026, NTH trades above its calculated fair value: price €2.43, fair value €2.17, a gap of about −11% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NTH?
No. The price is what the market pays today (€2.43); the fair value is what the company's own numbers justify (€2.17). For Naturhouse Health SA the two are €0.2600 per share apart. That gap is exactly why we show both numbers side by side.
How much is Naturhouse Health SA worth?
The market values Naturhouse Health SA at about €144M (market capitalisation, as of Sep 23, 2026). Per share that is €2.43; our models calculate a fair value of €2.17 per share.
What do the bullish and bearish scenarios say about NTH?
Our models span a range for Naturhouse Health SA: cautious scenario €1.73, base €2.17, optimistic €2.64 per share (as of Sep 23, 2026, price €2.43). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NTH?
Naturhouse Health SA trades at a price-to-earnings ratio of 14.3 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €2.17 is built from several models across several years. Other multiples: P/B 9.3, P/S 3.5, EV/EBITDA 11.3.
How solid is the balance sheet of Naturhouse Health SA (NTH)?
Balance-sheet figures for Naturhouse Health SA (as of Sep 23, 2026): return on equity 40.8%. They feed the Quality Score of 89/100, which measures business quality independently of the share price.
How far is NTH from its 52-week high?
Naturhouse Health SA trades at €2.43, about 9% below its 52-week high of €2.67 and 33% above the low of €1.83 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of €2.17 is for.
Which stocks are comparable to Naturhouse Health SA?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, The Kraft Heinz Company, Foshan Haitian Flavouring and Food Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Naturhouse Health SA stock attractive at the current price?
The data as of Sep 23, 2026: price €2.43, calculated fair value €2.17 (−11%), Quality Score 89/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NTH calculated?
We run Naturhouse Health SA through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €2.17, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Naturhouse Health SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Naturhouse Health SA (NTH)?
The closing price on Sep 24, 2026 was €2.43. Our model-based fair value is €2.17, about −11% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Naturhouse Health SA right now?
The price sits in the upper half of our model range, so the margin of safety is thin. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Naturhouse Health SA (NTH) come from?
Earnings per share at Naturhouse Health SA grew −8.2 % a year from 2014 to 2025. Broken into its drivers: revenue per share −7.2 %, EBIT margin −1.5 %, tax rate +0.6 %, residual (interest, one-offs) −0.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Naturhouse Health SA
How large is the market capitalisation of Naturhouse Health SA (NTH)?
The market capitalisation of Naturhouse Health SA is €144M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Naturhouse Health SA (NTH)?
The price-to-sales ratio of Naturhouse Health SA is 3.03 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Naturhouse Health SA (NTH)?
Earnings per share at Naturhouse Health SA are €0.1700 (price ÷ EPS = P/E 14.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Naturhouse Health SA (NTH)?
The dividend yield of Naturhouse Health SA is 11.7% (payout 168%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Naturhouse Health SA (NTH)?
The net margin of Naturhouse Health SA is 21.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Naturhouse Health SA (NTH)?
The return on equity (ROE) of Naturhouse Health SA is 40.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Naturhouse Health SA (NTH)?
On an EBIT basis the return on assets of Naturhouse Health SA is 33.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Naturhouse Health SA (NTH)?
The operating margin of Naturhouse Health SA is 23.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Naturhouse Health SA (NTH)?
Revenue at Naturhouse Health SA is growing −0.8% versus a year earlier (3y avg −3.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Naturhouse Health SA (NTH)?
Earnings per share at Naturhouse Health SA are growing +8.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Naturhouse Health SA (NTH) hold?
Naturhouse Health SA holds more cash than debt, €10.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Naturhouse Health SA in the live analysis
One click puts Naturhouse Health SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
